The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.
Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.